



Company contact: Maria Maccicchini, CEO
QR Pharma, Inc.
610 727 3710
maccicchini@qrpharma.com

QR Pharma Announces Publication on Posiphen Clinical Trials Showing Promise for Alzheimer's Patients

Berwyn, PA, July 17, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative disorders, announced today that a report on the early stage clinical trials of its lead compound Posiphen® appeared online July 11, 2012 in the Journal of Neurology, Neurosurgery & Psychiatry and can be found online at: <http://jnnp.bmj.com/content/early/2012/07/10/jnnp-2012-302589.full>.

Posiphen has been shown in three early stage clinical studies to be safe and to significantly lower levels of amyloid beta, tau and inflammatory markers, which are the hallmarks of Alzheimer's disease. The dosing, tolerability, and proof of mechanism studies were conducted by an international group of investigators testing Posiphen both in healthy volunteers and in patients with mild cognitive impairment (MCI), a condition that often progresses to Alzheimer's. Posiphen works by inhibiting the production of neurotoxic proteins that derive from amyloid precursor protein (APP) and tau. This data provides key evidence to move the drug forward for further human testing.

About Posiphen® QR's lead compound, Posiphen®, is a small orally active compound with high blood brain barrier permeability. Posiphen reduces the levels of toxic proteins in the brains of patients with neurodegenerative disorders back to the levels found in normal healthy volunteers. By normalizing brain levels of alpha synuclein, beta amyloid and tau, it provides an avenue to treat Alzheimer's and Parkinson's disease early so as to prevent the onset or diminish the severity of cognitive decline. Since neurotoxic proteins cause inflammation in the brain, lowering their levels reduces inflammatory factors and lowers inflammation.

About QR Pharma, Inc. Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders. QR currently has three product development programs - Posiphen for early stage Alzheimer's and Parkinson's disease, and BNC for advanced Alzheimer's disease. For more information on QR Pharma, please visit the company's website, www.qrpharma.com.

Contact: Maria L. Maccicchini, CEO
Tel: 610 727 3710
maccicchini@qrpharma.com
www.qrpharma.com

[Close this Window](#)